Clinical Trials

Lymphoma, Lymphoma, T-Cell

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

9 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

16 enrolled

Lymphoma, T-Cell, Cutaneous

NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

5 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT01755975 2024-11-07

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Phase 3 Active not recruiting

49 enrolled 15 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

93 enrolled 19 charts

Lymphoma, Lymphoma, T-Cell

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

27 enrolled 13 charts

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT00020202 2024-03-04

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Genetic Diseases, Inborn, Small Cell Lung Carcinoma

NCT03742921 2023-12-06

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Completed

150 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03534180 2023-10-19

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

12 enrolled 8 charts

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01846390 2023-08-04

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

21 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT00104884 2023-06-28

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase 2 Terminated

4 enrolled 4 charts

Dermatologic

Melanoma

NCT01796002 2023-01-10

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase 3 Completed

421 enrolled

Lymphoma, T-Cell, Peripheral

NCT01947140 2022-11-23

PDX+Romi

DermatologicLymphoidOther hematologic neoplasmPlasma cell

57 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03770000 2022-10-28

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

33 enrolled 13 charts

Lymphoma, T-Cell

NCT03141203 2022-05-18

RomiCar

50 enrolled

Lymphoma, T-Cell, Peripheral

NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase 1/2 Recruiting

148 enrolled

Lymphoma, T-Cell

NCT00084682 2021-03-05

Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

14 enrolled 6 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01302808 2021-01-20

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 1/2 Active not recruiting

17 enrolled 12 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

NCT03547700 2021-01-19

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

11 enrolled

Lymphoma, T-Cell, Peripheral

NCT02181218 2020-11-17

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

24 enrolled

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Phase 1 Withdrawn

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT01902225 2020-06-09

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

24 enrolled

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT01742793 2020-03-04

RID

12 enrolled

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell

NCT00426764 2020-02-11

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

131 enrolled 16 charts

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00048334 2019-12-12

Depsipeptide to Treat Thyroid and Other Advanced Cancers

28 enrolled

Tumor-Agnostic

Neoplasms

NCT00765102 2019-11-25

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Phase 2 Terminated

32 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT01324310 2019-11-25

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

LymphoidOther hematologic neoplasm

15 enrolled 21 charts

Lymphoma, Hematologic Neoplasms

NCT01324323 2019-11-25

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

LymphoidOther hematologic neoplasm

14 enrolled 21 charts

Lymphoma, Hematologic Neoplasms

NCT00106301 2019-11-18

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

2 enrolled

Genitourinary

Carcinoma, Renal Cell, Prostatic Neoplasms

NCT00106418 2019-11-18

A Research Study for Patients With Prostate Cancer

35 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

102 enrolled 15 charts

Lymphoma, T-Cell, Cutaneous

NCT00379639 2019-10-30

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

36 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00106613 2019-10-18

A Research Study for Patients With Metastatic Renal Cell Carcinoma

30 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01822886 2019-10-14

FIL_GEMRO

20 enrolled 11 charts

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT01738594 2019-08-29

Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

7 enrolled 11 charts

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01456039 2019-02-11

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

51 enrolled 34 charts

Lymphoma, T-Cell, Peripheral

NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

26 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02061449 2018-12-24

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

3 enrolled

Lymphoma, T-Cell, Cutaneous

NCT03355768 2018-12-19

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Phase 3 Withdrawn

Lymphoma, T-Cell, Peripheral

NCT01590732 2018-09-19

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

22 enrolled

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 3 Completed

271 enrolled 25 charts

Lymphoma, T-Cell, Peripheral

NCT00007345 2017-05-16

Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma

131 enrolled 18 charts